Sartocon Slice 50: Sartorius Stedim Biotech presents a new small-scale crossflow device
Perfect for process development applications: SSB’s new small-scale and single-use filter device Sartocon Slice 50
Designed for use in biotechnological applications, especially for membrane screening and small-volume process development.
Sartorius Stedim Biotech (SSB) has launched the single- use ultrafilter Sartocon Slice 50. The new crossflow filter device is designed for use in biotechnological applications, especially for membrane screening and small-volume process development.
Sartocon Slice 50 is offered as an encapsulated and ready-to-use crossflow module with a filter area of 50 cm2 and a wide variety of molecular weight cutoffs. The cGMP validated self-contained unit eliminates the need for a compression holder and is available in a choice of two polymers: The Hydrosart membrane is a stable polymer suitable for a broad pH range and can be depyrogenated using NaOH at elevated temperatures. It is extremely hydrophilic, making it non-protein-binding and virtually non-fouling, and delivers an exceptional high flux. The polyethersulfone membrane (PESU), which is well established in the biotechnological and pharmaceutical industries, is a stable polymer that is ideal for a broad pH and temperature range.
A major benefit of the new crossflow filter device is its linear scalability, along with identical materials of construction. This eases transfer of process development results to the next scale up level.
Sartocon Slice 50 can easily be interfaced with SSB’s recently launched SARTOFLOW Smart benchtop crossflow system, as well as with many other laboratory-scale filtration systems.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.